Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 8 |
| 1.1 List of Tables | 8 | 2 |
| 1.2 List of Figures | 10 | 2 |
| 2 Global Monoclonal Antibodies Market: Introduction | 12 | 2 |
| 2.1 GBI Research Report Guidance | 13 | 1 |
| 3 Global Monoclonal Antibodies Market: Market Characterization | 14 | 15 |
| Introduction | 14 | 1 |
| 3.2 Revenue Forecasts for the Global MAbs Market Potential | 14 | 1 |
| 3.2.1 MAbs Treatment Potential | 14 | 2 |
| 3.2.2 Drug Prices | 16 | 1 |
| 3.2.3 Market Potential | 17 | 1 |
| 3.2.4 Market Potential Segmentation | 18 | 1 |
| 3.3 Revenue Forecasts of Global MAbs Market Actual Market | 19 | 1 |
| 3.3.1 MAbs Actual Treatment Population | 19 | 1 |
| 3.3.2 Actual Sales | 20 | 1 |
| 3.3.3 Actual Sales Segmentation | 21 | 2 |
| 3.4 Treatment Usage Patterns | 23 | 1 |
| 3.5 Global MAbs Trends | 24 | 1 |
| 3.5.1 Market Trends | 24 | 1 |
| 3.5.1.1 Big Pharmaceutical Companies Venturing into MAbs Market | 24 | 1 |
| 3.5.2 Technology Trends | 25 | 1 |
| 3.5.2.1 State-of-the-art R&D Technologies Expanding the Applications of MAbs to New Therapeutic Indications | 25 | 1 |
| 3.5.2.2 New Screening Technologies to Foster Monoclonal Antibody Development | 25 | 1 |
| 3.6 Product Trends | 25 | 1 |
| 3.6.1 Research and Development Focus Shifted Towards Humanized and Fully Humanized MAbs | 25 | 1 |
| 3.6.1.1 Horizontal Indication Expansion of Existing Mabs | 26 | 1 |
| 3.7 Global MAbs Market Drivers | 26 | 1 |
| 3.7.1 Gradual Growth in the Uptake of MAbs Have Driven the Monoclonal Antibody Sales Growth | 26 | 1 |
| 3.7.2 Improved Side-effect Profiles and Tolerance of MAbs Therapy | 26 | 1 |
| 3.7.3 Lack of Effective Conventional Therapies Accelerates Utilization of MAbs | 26 | 1 |
| 3.7.4 Expanded Indications Opens up New Potential Patient Group | 27 | 1 |
| 3.7.5 Lack of Generics Augmented the Sales Growth of MAbs | 27 | 1 |
| 3.8 Global MAbs Market Restraints | 27 | 1 |
| 3.8.1 High Cost of MAbs Hampering the Growth of Treatment Population | 27 | 1 |
| 3.8.2 Adverse Effects Generation of Antibodies against MAbs in Patients Receiving Monoclonal Antibody Therapy | 27 | 1 |
| 3.8.3 Industry Challenges Majority of MAbs Receive Approvals as Last Option Therapies | 28 | 1 |
| 3.9 Unmet Needs | 28 | 1 |
| 3.9.1 The High Cost of MAb Therapies is the Major Unmet Need and it is Also Responsible for Low Utilization by Patients | 28 | 1 |
| 3.9.2 MAbs Do Not Cure the Disease; They either Treat Signs and Symptoms or Decelerate Cell Proliferation | 28 | 1 |
| 4 Global MAbs Market Potential: Therapeutic Distribution | 29 | 24 |
| 4.1 MAbs Market Potential in HER2 Breast Cancer (Adjuvant and Metastatic) | 29 | 1 |
| 4.1.1 Introduction | 29 | 1 |
| 4.1.1.1 Epidemiology | 29 | 1 |
| 4.1.1.2 Diagnosis | 30 | 1 |
| 4.1.1.3 Treatment | 30 | 1 |
| 4.1.2 Prescription Population | 31 | 1 |
| 4.1.3 Annual Cost of Therapy | 32 | 1 |
| 4.1.4 Market Potential | 33 | 1 |
| 4.2 MAbs Market Potential in Bone Metastases and Bone Loss Due to Cancer Therapy | 34 | 1 |
| 4.2.1 Introduction | 34 | 1 |
| 4.2.1.1 Epidemiology | 34 | 1 |
| 4.2.1.2 Diagnosis | 35 | 1 |
| 4.2.1.3 Treatment | 35 | 1 |
| 4.2.2 Prescription Population | 35 | 1 |
| 4.2.3 Annual Cost of Therapy | 36 | 1 |
| 4.2.4 Market Potential | 37 | 1 |
| 4.3 MAbs Market Potential in Relapsing-remitting Multiple Sclerosis (RRMS) | 38 | 1 |
| 4.3.1 Introduction | 38 | 1 |
| 4.3.1.1 Epidemiology | 38 | 1 |
| 4.3.1.2 Diagnosis | 39 | 1 |
| 4.3.1.3 Treatment | 40 | 1 |
| 4.3.2 Prescription Population | 40 | 1 |
| 4.3.3 Annual Cost of Therapy | 41 | 1 |
| Market Potential | 42 | 1 |
| 4.4 MAbs Market Potential in Metastatic Non-Small Cell Lung Cancer (NSCLC) | 43 | 1 |
| 4.4.1 Introduction | 43 | 1 |
| 4.4.1.1 Epidemiology | 43 | 1 |
| 4.4.1.2 Diagnosis | 43 | 1 |
| 4.4.1.3 Treatment | 44 | 1 |
| 4.4.2 Prescription Population | 45 | 1 |
| 4.4.3 Annual Cost of Therapy | 45 | 1 |
| 4.4.4 Market Potential | 46 | 1 |
| 4.5 MAbs Market Potential in Rheumatoid Arthritis | 47 | 1 |
| 4.5.1 Introduction | 47 | 1 |
| 4.5.1.1 Epidemiology | 47 | 1 |
| 4.5.1.2 Diagnosis | 48 | 1 |
| 4.5.1.3 Treatment | 48 | 1 |
| 4.5.2 Prescription Population | 49 | 1 |
| 4.5.3 Annual Cost of Therapy | 50 | 1 |
| 4.5.4 Market Potential | 51 | 2 |
| 5 Global MAbs Market: Pipeline Analysis | 53 | 33 |
| Introduction | 53 | 1 |
| 5.2 MAbs Nomenclature | 53 | 1 |
| 5.3 Monoclonal Antibody Technology | 54 | 1 |
| 5.3.1.1 Hybridoma Technology | 54 | 1 |
| 5.3.1.2 FuCell Technology | 55 | 1 |
| Applications of MAbs | 55 | 1 |
| 5.4.1 Detection Assays | 55 | 1 |
| 5.4.1.1 ELISA | 55 | 1 |
| 5.4.2 Purification Techniques | 55 | 1 |
| 5.4.3 Gene Identification | 55 | 1 |
| 5.4.4 Applied Chemistry | 55 | 1 |
| 5.4.5 Disease Therapy | 56 | 1 |
| 5.5 Therapeutic Applications in Oncology | 56 | 1 |
| 5.5.1 Introduction | 56 | 1 |
| 5.5.2 Marketed Therapies | 56 | 1 |
| 5.5.2.1 Rituxan | 56 | 1 |
| 5.5.2.2 Campath | 57 | 1 |
| 5.5.2.3 Herceptin | 58 | 1 |
| 5.5.2.4 Mylotarg | 58 | 1 |
| 5.5.2.5 Zevalin | 59 | 1 |
| 5.5.2.6 Bexxar | 59 | 1 |
| 5.5.2.7 Erbitux | 60 | 1 |
| 5.5.2.8 Avastin | 61 | 1 |
| 5.5.2.9 Vectibix | 61 | 1 |
| 5.5.3 Therapies in Late Stage Pipeline | 62 | 1 |
| 5.5.3.1 CP-751,871 | 62 | 1 |
| 5.5.3.2 MK-0646 | 63 | 1 |
| 5.5.3.3 SGN-35 | 63 | 1 |
| 5.5.3.4 Trastuzumab-DM1 (T-DM1) | 63 | 1 |
| 5.5.3.5 CMC544 | 64 | 1 |
| 5.5.3.6 Arzerra | 64 | 1 |
| 5.5.3.7 Galiximab | 64 | 1 |
| 5.5.3.8 Lumiliximab | 65 | 1 |
| 5.5.3.9 Ipilimumab | 65 | 1 |
| 5.6 Therapeutic Applications in Autoimmune and Inflammatory Diseases | 66 | 1 |
| Introduction | 66 | 1 |
| 5.6.2 Marketed Therapies | 66 | 1 |
| 5.6.2.1 Remicade | 66 | 1 |
| 5.6.2.2 Humira | 67 | 1 |
| 5.6.2.3 Raptiva | 68 | 1 |
| 5.6.2.4 Tysabri | 69 | 1 |
| 5.6.2.5 Cimzia | 70 | 1 |
| 5.6.2.6 Ilaris | 70 | 1 |
| 5.6.2.7 Simponi | 71 | 1 |
| 5.6.3 Therapies in Late Stage Pipeline | 71 | 1 |
| 5.6.3.1 Stelara | 71 | 1 |
| 5.6.3.2 Benlysta | 71 | 1 |
| 5.6.3.3 ABT-874 | 72 | 1 |
| 5.6.3.4 Daclizumab | 73 | 1 |
| 5.6.3.5 Alemtuzumab | 73 | 1 |
| 5.7 Therapeutic Applications in Respiratory Diseases | 74 | 1 |
| 5.7.1 Introduction | 74 | 1 |
| Marketed Therapies | 74 | 1 |
| 5.7.2.1 Xolair | 74 | 1 |
| 5.7.3 Therapies in Late Stage Pipeline | 75 | 1 |
| 5.7.3.1 MEDI-528 | 75 | 1 |
| 5.8 Therapeutic Applications in Infectious Diseases | 75 | 1 |
| 5.8.1 Introduction | 75 | 1 |
| 5.8.2 Marketed Therapies | 76 | 1 |
| 5.8.2.1 Synagis | 76 | 1 |
| 5.8.3 Therapies in Pipeline | 76 | 1 |
| 5.8.3.1 ABthrax | 76 | 1 |
| 5.8.3.2 Numax | 77 | 1 |
| Therapeutic Applications in Organ Transplantation | 77 | 1 |
| 5.9.1 Introduction | 77 | 1 |
| 5.9.2 Marketed Therapies | 78 | 1 |
| 5.9.2.1 Orthoclone OKT3 | 78 | 1 |
| 5.9.2.2 Zenapax | 78 | 1 |
| 5.9.2.3 Simulect | 79 | 1 |
| 5.10 Therapeutic Applications in Cardiovascular Diseases | 79 | 1 |
| 5.10.1 Introduction | 79 | 1 |
| 5.10.2 Marketed Therapies | 80 | 1 |
| 5.10.2.1 Reopro | 80 | 1 |
| 5.10.3 Therapies in Pipeline | 81 | 1 |
| 5.10.3.1 TB-402 | 81 | 1 |
| 5.11 New Indications | 81 | 1 |
| 5.11.1 Central Nervous System | 82 | 1 |
| 5.11.1.1 Solanezumab | 82 | 1 |
| 5.11.2 Diabetes | 83 | 1 |
| 5.11.2.1 Otelixizumab | 83 | 1 |
| 5.11.2.2 Teplizumab | 83 | 1 |
| 5.12 Insights into Most Promising Drugs | 83 | 1 |
| Denosumab | 83 | 1 |
| 5.12.1.1 Introduction | 83 | 1 |
| 5.12.1.2 Mechanism of Action | 84 | 1 |
| 5.12.1.3 Clinical Trial Management | 84 | 1 |
| 5.12.1.4 Market Potential | 85 | 1 |
| 6 Global MAbs Market: M&A Landscape | 86 | 8 |
| 6.1 Overview | 86 | 1 |
| 6.1.1 Emergent BioSolutions acquires Avanir Pharmaceuticals | 86 | 1 |
| 6.1.2 MacroGenics acquires Raven Biotechnologies | 86 | 1 |
| 6.1.3 Thermo Fisher acquires Affinity BioReagents | 87 | 1 |
| 6.2 R&D Licensing Agreements | 87 | 1 |
| 6.2.1 Deals by Phase | 87 | 1 |
| 6.2.2 Deals by Geography | 87 | 1 |
| 6.2.3 Deals by Licensing Type | 88 | 1 |
| 6.2.4 Deals by Value ($) | 88 | 1 |
| 6.2.5 Preclinical | 89 | 1 |
| 6.2.5.1 AVP 21D9: | 89 | 1 |
| 6.2.5.2 DX-2240 | 89 | 1 |
| 6.2.5.3 Anti LIGHT Monoclonal Antibody | 89 | 1 |
| 6.2.5.4 Anti-L1 | 89 | 1 |
| 6.2.6 Phase I | 90 | 1 |
| 6.2.6.1 AMG 557 | 90 | 1 |
| 6.2.6.2 Elotuzumab | 90 | 1 |
| 6.2.7 Phase II | 91 | 1 |
| 6.2.7.1 R7159 | 91 | 1 |
| 6.2.7.2 GA101 | 91 | 1 |
| 6.2.8 Phase III | 92 | 1 |
| 6.2.8.1 Campath | 92 | 1 |
| 6.2.9 Approved | 92 | 1 |
| 6.2.9.1 Vectibix | 92 | 2 |
| 7 Global MAbs Market: Competitive Landscape | 94 | 34 |
| 7.1 Evolving competitive landscape | 94 | 1 |
| 7.1.1 Major players | 94 | 1 |
| 7.1.2 Key MAbs in the Market | 95 | 1 |
| 7.2 Company Benchmarking Analysis | 96 | 2 |
| 7.3 Roche/Genentech | 98 | 2 |
| 7.3.1 Key Monoclonal Antibody Drugs | 100 | 1 |
| 7.3.1.1 Rituxan | 100 | 1 |
| 7.3.1.2 Avastin | 101 | 1 |
| 7.3.1.3 Herceptin | 101 | 1 |
| 7.3.1.4 Lucentis | 102 | 1 |
| 7.3.1.5 Xolair | 102 | 1 |
| 7.3.1.6 Raptiva | 102 | 1 |
| 7.3.1.7 Actemra | 102 | 1 |
| 7.3.2 Key Indications of Interest | 102 | 1 |
| 7.3.3 Pipeline Analysis | 103 | 1 |
| 7.4 Abbott | 104 | 1 |
| 7.4.1 Key MAbs | 105 | 1 |
| 7.4.1.1 Humira | 105 | 1 |
| 7.4.2 Key Indications of Interests | 106 | 1 |
| 7.4.3 Pipeline Analysis | 106 | 1 |
| Johnson &Johnson | 106 | 1 |
| 7.5.1 Key MAbs | 107 | 1 |
| 7.5.1.1 Stelara | 107 | 1 |
| 7.5.1.2 Remicade | 107 | 1 |
| 7.5.2 Key Indications of Interest | 108 | 1 |
| 7.5.3 Pipeline Analysis | 108 | 1 |
| 7.6 Biogen Idec. | 109 | 1 |
| 7.6.1 Key MAbs | 110 | 1 |
| 7.6.1.1 Lumiliximab | 110 | 1 |
| 7.6.1.2 Rituxan (rituximab) | 110 | 1 |
| 7.6.1.3 Tysabri (natalizumab) | 111 | 1 |
| 7.6.2 Key Indications of Interest | 111 | 1 |
| 7.6.3 Pipeline Analysis | 111 | 1 |
| 7.7 Merck/Schering Plough | 112 | 1 |
| 7.7.1 Key MAbs | 113 | 1 |
| 7.7.1.1 Remicade | 113 | 1 |
| 7.7.1.2 Simponi | 113 | 1 |
| 7.7.2 Key Indications of Interest | 113 | 1 |
| 7.7.3 Pipeline Analysis | 114 | 1 |
| 7.8 AstraZeneca | 115 | 1 |
| 7.8.1 Key MAbs | 115 | 1 |
| 7.8.1.1 Synagis | 115 | 1 |
| 7.8.2 Key Indications of Interest | 116 | 1 |
| 7.8.3 Pipeline Analysis | 116 | 1 |
| 7.9 Bristol-Myers Squibb | 117 | 1 |
| 7.9.1 Key MAbs | 118 | 1 |
| 7.9.1.1 Erbitux | 118 | 1 |
| 7.9.2 Key Indications of Interest | 118 | 1 |
| Elan | 119 | 1 |
| 7.10.1 Key MAbs | 120 | 1 |
| 7.10.1.1 Tysabri | 120 | 1 |
| 7.10.2 Key Indications of Interest | 120 | 1 |
| 7.10.3 Pipeline Analysis | 121 | 1 |
| 7.11 Eli Lilly | 122 | 1 |
| 7.11.1 Key Monoclonal Antibody Drugs | 123 | 1 |
| 7.11.1.1 Reo Pro | 123 | 1 |